Evidence mapPaperPMID 20671217Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2010

Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.

Mark E Williams, Eduardo Lacson, Weiling Wang, J Michael Lazarus, Raymond Hakim

Abstract readComparative Study
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 98 citations in OpenAlex.

  1. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients.Journal of the American Society of Nephrology : JASN · 2013
    Trial
  2. Review
  3. Review
  4. Diabetes and Glucose Management in People on Hemodialysis.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  5. Article
  6. Observational
  7. Review
  8. Making sense of glucose sensors in end-stage kidney disease: A review.Frontiers in clinical diabetes and healthcare · 2022
    Review
  9. Risk Factors Associated with All-Cause Death Among Dialysis Patients with Diabetes.Medical science monitor : international medical journal of experimental and clinical research · 2021
    Observational
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Diabetes mellitus and renal failure: Prevention and management.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2015
    Review
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Mark E WilliamsRenal Unit, Joslin Diabetes Center, Boston, MA 02215, USA. mark.williams@joslin.harvard.edu
Eduardo Lacson
Weiling Wang
J Michael Lazarus
Raymond Hakim
Fresenius Medical Care North America (United States)Fresenius Medical Care (United States) · USJoslin Diabetes Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe benefits and risks of aggressive glycemic control in diabetes mellitus complicated by end-stage kidney failure remain uncertain but have importance because of the large patient population with inferior overall prognosis. Recent large observational studies with differing methodologies reached somewhat contrasting conclusions regarding the association of hemoglobin A1c with survival in diabetic chronic hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study supplements the authors' previous analysis (which found no correlation) by extending the follow-up period to 3 years and using time-dependent survival models with repeated measures. Among 24,875 nationally distributed study patients, 94.5% had type 2 diabetes, allowing additional analysis in the subset with type 1 diabetes. Data were collected at baseline and every quarter to a maximum of 3 years' follow-up.

resultsAdjusted standard and time-dependent Cox models indicated that only extremes of glycemia were associated with inferior survival. There was no effect modification by serum albumin levels, a marker of protein nutrition status, and no trend associated with random glucose measurements in a post hoc analysis. In type 1 diabetic patients, upper extreme hemoglobin A1c values indicated lower survival risk.

conclusionsSustained extremes of glycemia were only variably and weakly associated with decreased survival in this population. In the absence of randomized, controlled trials, these results suggest that aggressive glycemic control cannot be routinely recommended for all diabetic hemodialysis patients on the basis of reducing mortality risk. Physicians are encouraged to individualize glycemic targets based on potential risks and benefits in diabetic ESRD patients.

Indexed as

AdultAgedBiomarkersBlood GlucoseChi-Square DistributionDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NephropathiesFemaleFollow-Up StudiesGlycated HemoglobinHumansHypoglycemic AgentsKaplan-Meier EstimateKidney Failure, ChronicMaleBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSerum Albumin

Identifiers

PMID20671217
PMCPMC2974399
OpenAlexW2136112185

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.